Scarica l'app Stockscreener
29.48
4.02%
1.14
Precedente Chiudi:
$28.34
Aprire:
$28.73
Volume 24 ore:
378.20K
Relative Volume:
0.79
Capitalizzazione di mercato:
$1.52B
Reddito:
$413.05M
Utile/perdita netta:
$-27.67M
Rapporto P/E:
-52.55
EPS:
-0.561
Flusso di cassa netto:
$-30.75M
1 W Prestazione:
+1.34%
1M Prestazione:
-7.22%
6M Prestazione:
-6.83%
1 anno Prestazione:
-14.28%
Intervallo 1D:
$28.73
$29.90
Intervallo di 1 settimana:
$27.50
$29.90
Portata 52W:
$27.50
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Nome
Immunocore Holdings Plc Adr
Settore
Industria
Telefono
01235 5430281
Indirizzo
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
29.48 | 1.52B | 413.05M | -27.67M | -30.75M | -0.561 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-21 | Ripresa | JP Morgan | Overweight |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-07 | Aggiornamento | UBS | Sell → Buy |
| 2025-10-31 | Iniziato | Wells Fargo | Overweight |
| 2025-09-18 | Ripresa | Guggenheim | Neutral |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2025-05-27 | Iniziato | Deutsche Bank | Buy |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-10-24 | Iniziato | UBS | Sell |
| 2024-10-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Iniziato | Needham | Buy |
| 2023-08-16 | Iniziato | CapitalOne | Overweight |
| 2023-07-17 | Iniziato | Canaccord Genuity | Hold |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-30 | Iniziato | Guggenheim | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2022-12-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-30 | Iniziato | Barclays | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-08-08 | Iniziato | Cowen | Outperform |
| 2022-08-02 | Iniziato | BTIG Research | Buy |
| 2022-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-20 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | Goldman | Neutral |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
| 2021-03-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
Price to earnings ratio of Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh – HAN:6YG - TradingView
Editas Medicine, Inc. (EDIT) Stock Price & News - Syfe
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh - TradingView
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – HAN:6YG - TradingView
Form 8K Immunocore Holdings plc For: 14 September By Investing.com - Investing.com South Africa
Immunocore Achieves Full Enrollment in Phase 3 TEBE-AM Melanoma Study - Kalkine Media
Immunocore at cantor global healthcare conference: growth, trials and cash - Investing.com
Prime Medicine, Inc. (PRME) Stock Price & News - Syfe
Immunocore (IMCR) Technicals: Closes 1.65% Higher at $36.88 for the Current Session; Range View - dars.gov.et
Immunocore (IMCR) Technicals: Closes 1.65% Higher at $36.88 for the Current Session; Range View - dars.gov.et
ProKidney Corp. Class A (PROK) Stock Price & News - Syfe
Immunocore (IMCR) Earnings Review: The Available Earnings Metric Delivers a Miss; Share-Price Check: Shares Finish 2.77% Up at the CloseEarnings Surprise Stocks - careplusvn.com
Immunocore (IMCR) Earnings Review: The Available Earnings Metric Delivers a Miss; Share-Price Check: Shares Finish 2.77% Up at the CloseEarnings Surprise Stocks - dars.gov.et
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - MarketBeat
Q3 Earnings Forecast for Immunocore Issued By HC Wainwright - MarketBeat
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum - Yahoo Finance
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation? - Yahoo Finance
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss - TradingView
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - TradingView
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - Zacks Investment Research
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance Singapore
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Zacks Investment Research
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
Immunocore Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Immunocore posts Q2 2026 revenue beat as EPS misses - Investing.com
Immunocore Holdings earnings missed by $0.03, revenue topped estimates - Investing.com
Immunocore set to report earnings ahead of pivotal trial data - Investing.com
Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Stempoint Capital LP Purchases New Shares in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eversept Partners LP Takes Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Yahoo! Finance Canada
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Zacks Investment Research
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? - TradingView
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead - TradingView
IMCR|Immunocore Holdings PLC|Price:32.000|Chg%:-0.300 - TradingKey
Principal Financial Group Inc. Sells 139,306 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors - TradingView
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push - TradingView
Is it a good idea to invest in Immunocore stock right now? - MSN
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - TradingView
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
IMCR News | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
Immunocore Holdings Plc Adr Azioni (IMCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunocore Holdings Plc Adr Azioni (IMCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| David Berman | Affiliate |
May 21 '26 |
Proposed Sale |
29.15 |
65,000 |
1,894,638 |
0 |
| David Berman | Affiliate |
Apr 08 '26 |
Proposed Sale |
31.85 |
25,000 |
796,250 |
0 |
| David Berman | affiliate |
Mar 11 '26 |
Proposed Sale |
32.57 |
11,832 |
385,330 |
0 |
| Bahija Jallal | affiliate |
Feb 18 '26 |
Proposed Sale |
32.35 |
11,474 |
371,152 |
0 |
| Tina St Leger | affiliate |
Feb 18 '26 |
Proposed Sale |
32.35 |
1,000 |
32,347 |
0 |
| David Berman | affiliate |
Feb 18 '26 |
Proposed Sale |
32.35 |
5,965 |
192,951 |
0 |
| Berman David M | HEAD OF R&D |
Feb 18 '26 |
Sale |
32.35 |
5,965 |
192,968 |
5,859 |
| St Leger Tina Amber | CHIEF HR OFFICER |
Feb 18 '26 |
Sale |
32.35 |
1,000 |
32,350 |
1,119 |
| GOLL JOHN | SVP, FINANCE & CAO |
Feb 18 '26 |
Sale |
32.35 |
698 |
22,580 |
653 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER |
Feb 18 '26 |
Sale |
32.35 |
11,474 |
371,184 |
12,343 |
1.60%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):